OKYO Pharma to Present at Stifel Conference
Healthcare investors can meet OKYO leadership one-on-one or watch the November 12 webcast, archived for 90 days.
Updated on Nov. 5, 2026 in Healthcare

OKYO Pharma will take part in the Stifel 2026 Healthcare Conference November 10-12, 2026, with CEO Robert J. Dempsey presenting at 9:20 a.m. ET on November 12. The event is of interest to healthcare investors and operators tracking clinical-stage biopharma activity.
Why it matters
Investor conferences like this are a channel through which clinical-stage companies communicate pipeline progress and arrange one-on-one meetings with institutional investors. For healthcare businesses and their advisors, the scheduled presentation offers a near-term signal on how the company is positioning its lead program.
The company's presentation is scheduled for 9:20 a.m. ET on November 12, 2026, within a three-day conference running November 10-12. The webcast will be archived for 90 days after the event, and the source provides no comparator figures for the company's financial or clinical performance.
The players
OKYO Pharma Limited
A clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.
Stifel
A U.S. investment bank whose healthcare conference brings together public companies and institutional investors.
The details
OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases. Its lead candidate, urcosimod, recently announced first patients enrolled in the Phase 3 NEPTUNE trial for neuropathic corneal pain. Investors can arrange one-on-one meetings through their Stifel representative, and a live webcast will be available through Stifel's platform.
Timeline
November 10-12, 2026: Stifel 2026 Healthcare Conference, with OKYO participating.
November 12, 2026 at 9:20 a.m. ET: CEO Robert J. Dempsey's scheduled presentation.
Following the conference: webcast archived on the OKYO website for 90 days.
Market Landscape
Clinical-stage companies commonly use mid-November healthcare investor conferences to update the market between trial milestones. The NEPTUNE Phase 3 trial's recent enrollment start places this appearance in the period when investor interest in pipeline progress is typically highest.
Operators and investors tracking pipeline-stage biopharma should note the scheduled presentation and the availability of one-on-one meetings through Stifel representatives. Those evaluating vendor or partner relationships in clinical-stage ophthalmology should watch for pipeline updates at the event.
The takeaway
Treat the November 12 presentation as a checkpoint on the NEPTUNE program's progress, and calendar the 90-day webcast archive window if you want to review the remarks. Investors seeking a meeting should contact their Stifel representative directly.
What happens next
CEO Robert J. Dempsey presents at 9:20 a.m. ET on November 12, 2026, at the Stifel 2026 Healthcare Conference in New York.
Further reading
For broader context on drug development and investor activity, explore the Healthcare section.
Source note: This article includes information reported by The Manila times.





